Skip to main content
The drug industry's voice for manufacturing excellence
Production
Development
Information Technology
Compliance
Quality & Risk
Sections
Production
Development
Information Technology
Compliance
Quality & Risk
Facilities
Sectors
Special
Webinars
Podcasts
eHandbooks & White Papers
Industry News
Magazine Archives
Contact
Newsletter Subscription
Contact Us
Advertise
Follow us on
https://www.facebook.com/pages/Pharmaceutical-Manufacturing/140261116014887
http://www.linkedin.com/groups?gid=1813799
http://twitter.com/PharmaMfg
Editors' (re)View
editreview
Lonza ups the ante in US with Merck KGaA deal, Samsung Biologics must respond
With Lonza’s creation of arguably the largest biologics CDMO network in the U.S., Samsung’s limited beachhead in America won’t be enough to compete.
Nov. 9, 2026
editreview
Lonza might not be in a capacity race, but Samsung Biologics is another case
Oct. 23, 2026
editreview
GLP-1 pill market fuels manufacturing race between Eli Lilly and Novo Nordisk
Sept. 25, 2026
editreview
I knew something was up when Cellares abruptly canceled my visit to New Jersey site
Aug. 26, 2026
editreview
WuXi AppTec’s scarlet letter and the escalating US-China geopolitical conflict
Aug. 11, 2026
editreview
Brewing beer, drug ingredients, and making the US supply chain more resilient
Aug. 7, 2026
editreview
Trump’s proposed tariffs on imported generic drugs would threaten US supply chain
July 24, 2026
editreview
Why wasn’t WuXi Biologics added to DoD’s 1260H List like WuXi AppTec?
June 26, 2026
editreview
Japan’s pressured pharma companies, peptides, and a growing reliance on CDMOs
May 29, 2026
Looking for Something?
Load More Content
